Tracy Bahl Discusses OneOncology's Fundamental Priorities and Excitement for the Future

November 21, 2019

The momentum that OneOncology has in the marketplace creates an exciting environment for those involved, and those seeking to become involved, in our organization, said Tracy Bahl, MBA, president and chief executive officer of OneOncology.

The momentum that OneOncology has in the marketplace creates an exciting environment for those involved, and those seeking to become involved, in our organization, said Tracy Bahl, MBA, president and chief executive officer of OneOncology.

Transcript

With an increasing emphasis being placed on genetic testing and genetic counseling, is this a priority for community practices?

Well, it certainly is for OneOncology. Dr. Lee Schwartzberg, who’s our chief medical officer, has made this 1 of his fundamental priorities—advancing the science of genetic testing and genetic care that allow us to target our specific therapies in a way that advances better outcomes at a lower cost. It is something that is a principal focus for him in his clinical team.

Looking back on its first year, what are your biggest takeaways from OneOncology and where do you go from here?

Well, we’ve been around now for 1 year. It was our 1-year birthday just a few days ago, and in that year, we’ve partnered with 4 outstanding community oncology practices, we’ve built a foundation of operating as well as technical data and analytic capabilities that really [make] us really excited for the future. I guess I’m more excited for our next year than I was for our first one, given how much momentum we have in the marketplace and the truly incredible clinicians that are part of our organization today, and those that are seeking to become part of our organization long into the future. We’re really excited about what the next year holds.